Status:
COMPLETED
Neoadjuvant Stereotactic Body Radiation Therapy for Resectable Adenocarcinoma of the Pancreatic Head and/or Body
Lead Sponsor:
University of Cincinnati
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
The purpose of this study is to test the safety of focused radiation (Stereotactic Body Radiation Therapy, SBRT) on patients with pancreatic cancer that will be removed surgically.
Eligibility Criteria
Inclusion
- Age \>18 years.
- Histologically confirmed pancreatic adenocarcinoma of the head and/or body; at least the majority of the histopathologic specimen must be identified as adenocarcinoma.
- Pancreatic tumors must be considered resectable at time of treatment planning. Definition of resectable: no metastases, less than 180 degree involvement of superior mesenteric vein or portal vein, no involvement of hepatic artery, superior mesenteric artery or celiac artery
- No active infection requiring hospitalization
- Adequate labs
- Life expectancy \> 3 months.
- Patient is to have received chemotherapy prior to enrollment. This will typically consist of 3-4 cycles of chemotherapy. Patients will have a 2 week break between last chemotherapy administration and start of SBRT.
Exclusion
- Presence of metastatic disease.
- Infections requiring systemic antibiotic treatment.
Key Trial Info
Start Date :
August 27 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 12 2019
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT02208024
Start Date
August 27 2014
End Date
May 12 2019
Last Update
April 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Cincinnati
Cincinnati, Ohio, United States, 45219